Novartis has expanded its collaboration with Monte Rosa Therapeutics, committing up to $5.7 billion to develop molecular glue degraders targeting immune-mediated diseases. The deal includes an upfront payment of $120 million and options to license two preclinical immunology programs. Monte Rosa’s AI-powered QuEEN platform aids in identifying selective protein degraders. This marks Novartis’ fourth large immunology investment in the past month, emphasizing its dedication to novel therapeutic approaches.